Aromatase inhibitors (with ovarian function suppression for premenopausal survivors) (vs. no endocrine therapy) lead to greater reductions in the number of contralateral breast cancers than tamoxifen (vs. no endocrine therapy) across all treatment durations. This evidence concerns the gene CYP19A1 and breast carcinoma.